http://ipkitten.blogspot.com/2025/08/an-immunogenic-composition-is-not.html
In the recent Board of Appeal decision T 0070/23, GSK argued that its “immunogenic composition” product claim should be interpreted as limited by its efficacy as a vaccine, particularly in view of a description definition of the term. However, the Board of Appeal found both that product claims should not be interpreted as comprising therapeutic effects and that the description definitions do
Content reproduced from The IPKat as permitted under the Creative Commons Licence (UK).
